Press Release · Press Releases
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP...
This press release summary is reproduced from the issuer's public feed.
Read the full release at PR NewswireOriginal publisher: PR Newswire
Spotted an error? Request a correction · Corrections Policy
Related stories
Best Protective iPhone Cases for 2026: Top Slim and Drop-Protection Options for iPhone 18 Pro & iPhone 18 Pro Max Recommended by Consumer365
NEW YORK, Oct. 25, 2026 /PRNewswire/ -- Consumer365 has recognized TORRAS in its review of the best iPhone cases for 2026, highlighting the Ostand Q3 Air and Ostand Q3 Air Pro as two options designed for iPhone 18 Pro & iPhone 18 Pro Max users seeking a balance between slim everyday...
PR Newswire ·
APOD: 2026 October 25 – Dark Matter in a Simulated Universe
APOD Science APOD APOD: 2026 October 25 – Dark… Today’s APOD Archive Submissions Index Search Calendar RSS Education About Discuss APOD Astronomy Picture of the Day Discover the cosmos! Each day a different image or photograph of our fascinating universe is featured, along with a brief explanation written by a professional astronomer. Dark Matter […]
NASA ·
TCL Zhonghuan, REI Expo 2026'da Güneş Enerjisi Yenilikleriyle Hindistan'ın Enerji Dönüşümüne Öncülük Ediyor
BÜYÜK NOIDA, Hindistan, 25 Ekim 2026 /PRNewswire/ -- Yenilenebilir Enerji Hindistan Fuarı (REI), 22 Ekim'de Büyük Noida'daki Hindistan Fuar Merkezi'nde kapılarını açtı. Güney Asya'nın önde gelen yenilenebilir enerji sektörü etkinliklerinden biri olan bu yılki fuar, dünyanın dört bir...
PR Newswire ·
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levels First-line treatment options...
PR Newswire ·
Ping An Highlights Green Development Initiatives at International Communication Seminar in Shenzhen Ahead of APEC 2026
HONG KONG and SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- The Seminar on International Communication of Chinese and Foreign Enterprises' Green Development and Global Contributions was held at the Ping An Finance Center in Shenzhen on October 23. Hosted by the China Public Relations...
PR Newswire ·
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...
PR Newswire ·